Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
miR-135b is a microRNA that acts as a post-transcriptional regulator of gene expression. In the context of oncology, it has been shown to modulate the levels of androgen receptor (AR) and estrogen receptor (ER) in prostate and breast cancer cells, respectively. By targeting these receptors and other genes such as HIF1AN (Hypoxia-inducible factor 1-alpha inhibitor), miR-135b influences cell proliferation, oxygen homeostasis, angiogenesis, and glycolytic metabolism. Research suggests it may serve as a tumor suppressor or oncogene depending on the tissue context, but in the provided abstract, its overexpression inhibits growth in hormone-receptor-positive cancer cells.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on miR-135b.